The ocular surface最新文献

筛选

英文中文

Application of Stem Cell-Derived Exosomes in Anterior Segment Eye Diseases: A Comprehensive Update Review.

The ocular surface Pub Date : 2025-01-28 DOI: 10.1016/j.jtos.2025.01.012

Masoud Khorrami-Nejad, Hesam Hashemian, Ali Majdi, Khosrow Jadidi, Hossein Aghamolaei, Ali Hadi

{"title":"Application of Stem Cell-Derived Exosomes in Anterior Segment Eye Diseases: A Comprehensive Update Review.","authors":"Masoud Khorrami-Nejad, Hesam Hashemian, Ali Majdi, Khosrow Jadidi, Hossein Aghamolaei, Ali Hadi","doi":"10.1016/j.jtos.2025.01.012","DOIUrl":"https://doi.org/10.1016/j.jtos.2025.01.012","url":null,"abstract":"Mesenchymal stem cell (MSC) therapy has emerged as a promising approach for addressing various eye-related conditions. Yet, its clinical application faces challenges due to issues such as limited biocompatibility and difficulties in effectively delivering treatment to specific ocular tissues. Recent studies have shifted attention towards MSC-derived exosomes, which share similar regenerative, reparative, and immunomodulatory capabilities with their origin cells. This review delves into the latest research on the use of MSC-derived exosomes for treating anterior segment diseases of the eye. It explores the exosomes' composition, biological functions, and the methods used for their isolation, as well as their roles in disease progression, diagnosis, and therapy. The review critically assesses the therapeutic advantages and mechanisms of action of MSC-derived exosomes in treating conditions like dry eye disease, Sjogren's syndrome, keratoconus, corneal lesions, and corneal allograft rejection. Additionally, it discusses the obstacles and future prospects of employing MSC-derived exosomes as innovative therapies for anterior segment eye diseases. This comprehensive overview underscores the significant potential of MSC-derived exosomes in transforming the treatment paradigm for anterior segment eye disorders, while also highlighting the necessity for further research to enhance their clinical application.","PeriodicalId":94247,"journal":{"name":"The ocular surface","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial. AZR-MD-001 0.5%硫化硒眼膏治疗隐形眼镜不适：一项对照、随机、临床试验。

The ocular surface Pub Date : 2024-12-28 DOI: 10.1016/j.jtos.2024.12.009

Fiona Stapleton, Mark Hinds, Jacqueline Tan, Lyndon Jones, Robin Chalmers, Charles Bosworth, Yair Alster

{"title":"AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial.","authors":"Fiona Stapleton, Mark Hinds, Jacqueline Tan, Lyndon Jones, Robin Chalmers, Charles Bosworth, Yair Alster","doi":"10.1016/j.jtos.2024.12.009","DOIUrl":"10.1016/j.jtos.2024.12.009","url":null,"abstract":"Background: Contact lens discomfort (CLD) is a common problem for CL wearers, and patients with CLD often have changes in meibomian gland function and structure. In a Phase 2 trial AZR-MD-001 0.5% (AZR) ophthalmic ointment improved meibomian gland dysfunction (MGD) in non-lens wearers. The current study evaluated the efficacy and safety of AZR in participants with CLD and concomitant MGD.Methods: Adults with CLD (Contact Lens Dry Eye Questionnaire-8 >12, range 0-37) and MGD (Meibomian Gland Secretion Score [MGS] ≤12, range 0-45) were randomized (1:1) to AZR:vehicle applied twice-weekly in a three-month multicenter, prospective, double-masked study. Endpoints included difference in change from baseline (CFB) in the number of Meibomian Glands Yielding Liquid Secretion (MGYLS), MGS, the ability to wear their lenses as long as desired, and safety.Results: At Month 3, AZR (n = 34) significantly increased the MGYLS and MGS versus vehicle (n = 33), with least squares mean difference (LSMD) CFB in MGYLS of 5.0 (SE = 0.47) for AZR and 1.6 (0.45) for vehicle, P < 0.0001; MGS of 13.8 (SE = 0.67) for AZR and 3.8 (SE = 0.68) for vehicle, P < 0.0001. Significantly more participants treated with AZR were able to wear lenses as long as desired (43% vs. 6%, P = 0.0023). The most common treatment-emergent adverse event (TEAE) was eye irritation (61.8% AZR; 0% vehicle). All TEAEs related to treatment were mild/moderate, transient, and did not result in discontinuation.Conclusion: AZR-MD-001 0.5% significantly improved MGD signs and hours of comfortable CL wear, demonstrating good efficacy, safety, and tolerability in those with CLD.","PeriodicalId":94247,"journal":{"name":"The ocular surface","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Readership awareness series – Paper 9: Retraction of a publication 读者意识系列 - 文件 9：撤回出版物

The ocular surface Pub Date : 2024-01-17 DOI: 10.1016/j.jtos.2024.01.008

Mohammad Javed Ali, Ali Djalilian

引用次数: 0